<?xml version="1.0" encoding="UTF-8"?>
<p>The need to protect the patient from increased risks needs changes through two complementary approaches: (i) improving the regulatory procedures and their guidance documents in the pre-registration phase, recognizing that regulators should step in with improved regulatory guidance and better clarification of procedures; and (ii) whenever comparative clinical data is still not available (provided by appropriately designed clinical trials), the need for adequate safety and efficacy data—if interchangeability is to be considered—might also include appropriate post-marketing risk management programmes, depending on a risk appraisal that has to be considered for each individual product, based only on the nature of the submitted relevant set of safety/efficacy data.</p>
